Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage.
A new tissue repair agent, RGTA11, is described for its ability to enhance colonic anastomosis repair and resistance to leakage. RGTA11 is a dextran derivative containing 110% carboxymethyl groups, 2.6% carboxymethyl benzylamide groups, and 36.6% carboxymethyl benzylamide sulfonate groups. RGTA11 was deemed efficient to protect the heparin-binding growth factors FGF2 against trypsin digestion. By this property RGTA11 mimicked heparin or heparan sulfate. We have also found that RGTA11 protected TGF beta 1 against trypsin digestion while heparin did not. RGTA11 was then tested in an in vivo wound-healing model of colonic anastomosis. Our results indicate that after 48 h, RGTA11- or RGTA11/FGF-2-treated animals presented a resistance of the anastomosis to leakage which was increased twofold (p < 0.05) over untreated controls. After 96 h and until day 7 there was no more difference with control animals. Our results suggest that RGTA11 presents potential clinical interest by preventing earlier leakage of colonic anastomosis.
Meddahi
A
A
Laboratoire de Recherche sur la Croissance, la Réparation et la Régénération Tissulaire (CRRET), CNRS URA 1813, Université Paris XII-Val de Marne, Créteil, France.
Benoit
J
J
Ayoub
N
N
Sézeur
A
A
Barritault
D
D
D000714:Anastomosis, Surgical; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D003106:Colon / Q000601:surgery*; D003911:Dextrans / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006868:Hydrolysis; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D011312:Pressure; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta / Q000737:chemistry; D014357:Trypsin / Q000737:chemistry; D014945:Wound Healing / Q000187:drug effects
D000925:Anticoagulants; D003911:Dextrans; C104129:RGTA11; D016212:Transforming Growth Factor beta; D006493:Heparin; D014357:Trypsin